Eight major RCTs of GLP-1RAs have investigated the cardiovascular outcomes, including the ELIXA trial of lixisenatide (250), the EXSCEL trial of exenatide ER (251), the LEARDER trial of liraglutide (252), the SUSTAIN-6 trial of subcutaneous semaglutide (253), the HARMONY trial of albiglutide (228), the REWIND trial of dulaglutide (254), the PIONEER trial of oral semaglutide (255), and the SELECT trial of subcutaneous semaglutide (199)
That said, unless your doctor says otherwise, there is usually no harm in taking a daily supplement
Pediatric dosing is typically weight-based and should be determined by a specialist
Efficacy of Epley's Maneuver in Treating BPPV Patients: A Prospective Observational Study
This is why patients using oral Mounjaro alternatives often report: Weak appetite suppression No change in cravings Lack of fat-loss momentum Zero metabolic difference Side effects without results A sense of this isnt doing anything In other words, most oral tirzepatide pill forms are not effective
Drug Metabolism Reviews 43, 138-151